Lipid alterations and cardiovascular risk associated with antiretroviral therapy;Alteraciones lipídicas y riesgo cardiovascular asociado a la terapia antirretroviral

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 10, 2006, Pages 637-648

  Masiá Canuto, Mar ^a,b   Bernal Morell, Enrique ^a   Gutiérrez Rodero, Félix ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

AIDS; Antiretroviral therapy; Cardiovascular risk; Dyslipidemia; HIV; Hyperlipidemia

Indexed keywords

ANTIRETROVIRUS AGENT; ATORVASTATIN; BEZAFIBRATE; EFAVIRENZ; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NELFINAVIR; NEVIRAPINE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; PHENOTYPE; REVIEW;

EID: 33846405295     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13095376     Document Type: Review

References (119)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F8.
2. Massip P, Marchou B, Bonnet E, Cuzin L, Montastruc JL. Lipodystrophia with protease inhibitors in HIV patients. Therapie. 1997;52:615.
3. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-9.
4. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
5. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-9.
6. Capeau J, Raffi F, Savés M (APROCO Study Group). Lipodystrophy and metabolic disorders in HIV. Antivir Ther. 2000;5 Suppl 5:55.
7. Henry K, Zackin R, Dube M, Hammer S, Sprecher D, Currier J. ACTG 5056: C-Reactive Protein (CRP) levels and cardiovascular risk status for a cohort of HIV-1-infected persons durably suppressed on an indinavir (IDV)-containing regimen (abstract 694-T). En: 9th Conference on Retroviruses and Opportunistic Infections. Seattle 2002.
8. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, et al; Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals. Focus on protease inhibitor therapy. AIDS. 2001;15:329-34.
9. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 2000;14:F123-F8.
10. Seminari E, Pan A, Voltini G, Carnevale G, Maserati R, Minoli L, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis. 2002;162:433-8.
11. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:57-62.
12. Mary-Krause M, Cotte L, Simon-Coutellier A, Partisani M, Costagliola D. Myocardial infarction (MI) in HIV seropositive men in the era of HAART treatments in France. XIII International AIDS Conference; 2000, July 9-14; Durban.
13. Holmberg S, Moorman A, Williamson JM, Tong TC, Ward DJ, Wood KC, et al; HIV Outpatient Study (HOPS) investigators. Protease Inhibitor and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747-8.
14. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
15. El Sadr W, Reiss P, De Wit S, De Wit S, D'Arminio Monforte A, Thiébaut R, et al. Relationship between prolonges exposure to combination ART and myocardial infarction: effect of sex, age, and lipid changes. 12th Conference on Retroviruses and Opportunistic Infections; 2005, February 22-25; Boston.
16. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al; DAD study group. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy: results from the D:A:D Study. AIDS. 2003;17:1179-93.
17. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect. 2001;42:181-8.
18. Dubé MP, Qian D, Edmonson-Melancon H. Prospective study of the effects of amprenavir-based therapy on glucose and lipid metabolism in HIV-infected patients. Antivir Ther. 2000;5 Suppl 5:26.
19. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15:F1-F9.
20. Clumeck N, Brun S, Sylte J, Isaacson J, Chen S, Lazzarin A, et al. Kaletra (ABT-378/r) and efavirenz: one-year safety/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patient. 8th Conference on Retroviruses and Opportunistic Infections; 2001, February 4-8; Chicago.
21. Bernstein B, Moseley J, King M. Safety of Kaletra: data from phase II and phase III clinical trials. 1st International AIDS Society Conference on HIV pathogenesis and treatment; 2001, July 8-11; Buenos Aires.
22. Gutiérrez F, Padilla S, Navarro A, Masía M, Hernández I, Ramos J, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/rironavir-containing regimens. J Acquir Immune Defic Syndr. 2003;33:594-600.
23. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 1995;333:1528-33.
24. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al; M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-46.
25. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV cohort study. Circulation. 1999;100:700-5.
26. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
27. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63-F70.
28. Van der Valk M, Kastelein JJ, Murphy RL, Van Leth F, Katlama C, Horban A, et al; Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407-14.
29. Dubé MP, Qian D, Edmondson-Melançon H, Sattler FR, Goodwin D, Martinez C, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002;35:475-81.
30. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-62.
31. Johnson M, Beall G, Badley A. A phase III, randomized, double-blind trial of Kaletra (ABT-378/r) + stavudine (d4T) and lamivudine (3TC) vs nelfinavir + d4T/3TC. 5th International Congress on Drug Therapy in HIV Infection; 2000, October 22-26. Glasgow.
32. Van der Valk M, Dubé MP, Edmondson-Melançon H, Qian D, Aqeel R, Johnson DJ, et al. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquir Immune Defic Syndr. 2001;27:130-4.
33. Moyle GJ, Baldwin C. Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 1999;21:423-4.
34. Gerstoft J, Dragsted UB, Cahn P, Castagna A, Duran A, Hill A, et al. Final analysis of a randomized trial to evaluate safety and efficacy of indinavir/ritonavir versus saquinavir/ritonavir in adult HIV-infected patients. 42th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002, September 27-30. San Diego.
35. Noor MA, Mulvey R, Elosua C. Comparative effects of atazanavir alone and in combination with low concentration of ritonavir on triglyceride and cholesterol synthesis in vitro. Program and abstracts of the 6th International Workshop on Adverse Drug Reactions and Lipodystrophy. 2004, October 25-28. Washington.
36. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36:1011-9.
37. Johnson M, Grinsztejn B, Rodríguez C, Coco J, DeJesús E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-94.
38. Malan N, Krantz E, David N, Kastango K, Frederick D, Matthew M, et al, and the -089 Study Group. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. 13th Conference on Retroviruses and Opportunistic Infections; 2006, February 5-8. Denver.
39. Moyle G, Baldwin C. Lipid elevations during non-nucleoside RTI (NNRTI) therapy: a cross sectional analysis. Antivir Ther: 1999;4 Suppl 2:54.
40. Núñez M, Soriano V, Rodríguez-Rosado R, Martín L, González-Lahoz J. The SENC (Spanish Efavirenz vs Nevirapine Comparison) trial: preliminary results of a prospective, randomized, controlled, open-label study in HIV+ naïve individuals. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000, September 17-20. Toronto.
41. Van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1:E19.
42. Liappis AP, Roberts AD, Klouj A, Granger SL, Simon JR, Schuck SZ, et al. Plasma lipids and lipoprotein subclasses among efavirenz-treated HIV patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002, September 27-30. San Diego.
43. Matthews GV, Moyle GJ, Mandalia S, Bower M, Nelson M, Gazzard BG. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. J Acquir Immune Defic Syndr. 2000;24:310-5.
44. Kumar P, Rodríguez-French A, Thompson M, Tashima K, Williams V, Wannamaker P, et al. Prospective study of hyperlipidemia in art-naïve subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (ESS40002). 9th Conference on Retroviruses and Opportunistic Infections; 2002, February 24-28. Washington.
45. Gallant JE, Staszewski S, Pozniak AL, DeJesús E, Suleiman JM, Miller MD, et al. 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
46. Pozniak AL, Gallant JE, DeJesús E, Campo R, Arribas JR, Gazzard B, et al. Superior outcome for tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naïve patients. 3rd IAS Conference on HIV Pathogenesis and Treatment. 2005, July 24-27. Rio de Janeiro.
47. Constans J, Pellegrin JL, Peuchant E, Dumon MF, Pellegrin I, Sergeant C, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest. 1994;24:416-20.
48. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-52.
49. González de Requena D, Blanco F, García Benayas T, Jiménez-Nacher I, González-Lahoz J, Soriano V. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS. 2003;17:443-5.
50. Tseng A, Loutfy M, Phillips E, Walker S, Rachlis A. The relationship between lipid elevations and lopinavir concentrations in HIV-infected patients on LPV/r-containig salvage regimens. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2002, September 27-30. San Diego.
51. Calboreanu A, Dimet J, Treluyer JM, Abad S, Pecqueux L, Krivine A, et al. Relation between lopinavir plasma blood concentrations and hypertriglyceridemia in naive and protease inhibitors-experienced patients. 10th Conference on Retroviruses and Opportunistic Infections. 2003, February 10-14. Boston.
52. Clevenbergh P, Garraffo R, Dellamonica P. Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients. HIV Clin Trials. 2003;4:330-6.
53. Torti C, Quirós-Roldán E, Regazzi-Bonora M, De Luca A, Lo Caputo S, Di Giambenedetto S, et al. Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations. J Acquir Immune Defic Syndr. 2004;35:324-6.
54. Grunfeld C, Doerrler W, Pang M, Jensen P, Weisgraber KH, Feingold KR. Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1997;82:3734-40.
55. Lister RK, Youle M, Nair DR, Winder AF, Rustin MH. Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors. Lancet. 1999;353:678.
56. Fauvel J, Bonnet E, Ruidavets JB, Ferrieres J, Toffoletti A, Massip P, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS. 2001;15:2397-406.
57. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem. 2001;276:37514-9.
58. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881-3.
59. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7:1327-31.
60. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels-a prospective and cross-sectional evaluation. Atherosclerosis. 2002;165:285-92.
61. Schmitz M, Michl GM, Walli R, Bogner J, Bedynek A, Seidel D, et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr. 2001;26:225-35.
62. Kondo A, Muranaka Y, Ohta I, Notsu K, Manabe M, Kotani K, et al. Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem. 2001;47:893-900.
63. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
64. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. Available from http://www.idf.org/webdata/docs/ Metabolic_syndrome_definition.pdf. Accessed 2 September 2005.
65. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab. 1999;25:225-32.
66. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 1993;92:141-6.
67. Jericó C, Knobel H, Montero M, Ordóñez-Llanos J, Guelar A, Gimeno JL, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;1:132-7.
68. Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care. 2002;25:1253-4.
69. Baril L, Beucler I, Valantin MA, Bruckert E, Bonnefont-Rousselot D, Coutellier A, et al. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS. 2001;15:415-7.
70. Becker S, Rachlis A, Gill J, DeJesús E, Pierone G, Kirkland L, et al. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads - a prospective, randomized, multicenter, open-label study (DMP 049). 8th Conference on Retroviruses and Opportunistic Infections. 2001, February 4-8. Chicago.
71. Opravil, Yerly S, Lazzarin A, Furrer HJ, Chaves P, Verzazza P, et al. Protease inhibitor class-sparing maintenance therapy with abacavir (ABC) + lamivudine (3TC) + zidovudine (ZDV) in patients with long-term suppression of HIV-1 RNA. 7th Conference on Retroviruses and Opportunistic Infections. 2000, January 30-February 2. San Francisco.
72. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, et al; CNA30017 Study Team. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS. 2001;15:1517-26.
73. Saint-Marc T, Partisani M, Poizot-Martin I, Touraine JL. Reversibility of Peripheral Fat Wasting (Lipoatrophy) on Stopping Stavudine Therapy. 7th Conference on Retroviruses and Opportunistic Infections. 2000, January 30-February 2. San Francisco.
74. Carr A, Smith D, Workman C, Hoy J, Doong N, Amin J, et al. Switching stavudine or zidovudine to abacavir for HIV lipoatrophy: a randomized, controlled, open-label, multicentre, 24-week study. 9th Conference on Retroviruses and Opportunistic Infection. 2002, February 24-28. Seattle.
75. Martínez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805-10.
76. Tebas P, Yarasheski K, Powderly WG, Kane E, Marin D, Simpson J, et al. A prospective open label pilot trial of a maintenance nevirapine-containing regimen in patients with undetectable viral loads on protease inhibitor regimens for at least 6 months. 7th Conference on Retroviruses and Opportunistic Infections. 2000, January 30-February 2. San Francisco.
77. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, et al; Spanish Lipodystrophy Group. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr. 2001;27:229-36.
78. Martínez E, García-Viejo MA, Blanco JL, Bianchi L, Buira E, Conget I, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis. 2000;31:1266-73.
79. Viciana P, Alarcón A, Martín D, Serrano P, López-Cortés LF, Cordero E, et al. Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitors to efavirenz. 7th Conference on Retroviruses and Opportunistic Infections. 2000, January 30-February 2. San Francisco.
80. Bonnet E, Lepec R, Bluteau M, Herve R, Bernard J, Perret B, et al. Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz. 7th Conference on Retroviruses and Opportunistic Infections. 2000, January 30-February 2. San Francisco.
81. Negredo E, Cruz L, Paredes R. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis. 2002;34:504-10.
82. Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036-46.
83. Fisac AC, Fumero E, Crespo M, Rosón B, Virgili N, Ribera E, et al. A randomized trial of metabolic and body composition changes in patients switching from PI-containing regimens to abacavir, efavirenz or nevirapine). 9th Conference on Retroviruses and Opportunistic Infections. 2002, February 24-28. Seattle.
84. Sension M, Grinsztejn B, Molina J. AI424067: Improvement in lipid profiles after 12 weeks of switching to atazanavir from boosted or unboosted protease inhibitors in patients with no previous PI virologic failure and hyperlipidemia at baseline. 12th Conference on Retroviruses and Opportunistic Infections. 2005, February 22-25. Boston.
85. Gatell JM, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, et al. Efficacy of atazanavir (ATV) based HAART in patients switched from a stable PI or boosted PI (PI/r) treatment. Planned week 24 analysis of a phase IIIb 48 week multicenter, open-label, randomized, prospective trial. The SWAN study. 3rd IAS Conference on HIV Pathogenesis and Treatment. 2005, July 24-27. Rio de Janeiro.
86. Martínez E, Azuaje C, Antela A, Rivero A, Lozano F, Deig E, et al. Effects of switching to ritonavir-boosted atazanavir on HIV-infected patients receiving antiretroviral therapy with hyperlipidemia. 12th Conference on Retroviruses and Opportunistic Infections; 2005, February 22-25. Boston.
87. Kumar P, Rodríguez-French A, Thompson M, Tashima K, Williams V, Wannamaker P, et al. Prospective study of hyperlipidemia in art-naïve subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC/NFV (ESS40002). 9th Conference on Retroviruses and Opportunistic Infections; 2002, February 24-28. Washington.
88. Domingo P, Labarga P, Palacios R, Guerro MF, Terron JA, Elías MJ, et al; RECOVER Study Group. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS. 2004;18:1475-8.
89. Moyle G, Sabin C, Cartledge J, Johnson M, Wilkins E, Churchill D, et al. A randomized, open-label comparative trial of abacavir or tenofovir DF as replacement for a thymidine analogue in persons with lipoatrophy and suppressed HIV RNA on HAART: the RAVE study (abstract 44). 12th Conference on Retroviruses and Opportunistic Infections; 2005, February 22-25. Boston.
90. Madruga JVR, Cassetti I, Suleiman JMAH, Zhong L, Enejosa J, Cheng AK. Improvement in lipoatrophy and lipid abnormalities following switch from stavudine (d4T) to tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-infected patients: a 48 week follow-up from study 903e. 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005, July 24-27. Rio de Janeiro.
91. Milinkovic A, López S, Vidal S, Miró O, Fernández X, Arnaiz J, et al. A randomized open study comparing the effect of reducing stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine. 12th Conference on Retroviruses and Opportunistic Infections; 2005, February 22-25. Boston.
92. Doser N, Kübli S, Telentic A, Marzolini C, Chave JP, Feihl F, et al. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS. 2002;16:1982-3.
93. Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, et al; ACTG 5087 Study Team. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses. 2005;21:757-67.
94. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS. 2001;15:1503-8.
95. Miller J, Brown D, Amin J, Kent-Hughes J, Law M, Kaldor J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS. 2002;16:2195-200.
96. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS. 2003;17:851-9.
97. Baldini F, Di Giambenedetto S, Cingolani A, Murri R, Ammassari A, De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS. 2000;14:1660-2.
98. Murillas J, Martín T, Ramos A, Portero JL. Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS. 1999;13:1424-5.
99. Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy. 2000;20:1066-71.
100. Schliefer K, Wasmuth JC, Rockstroh JK, Spengler U. Treatment of PI-induced hyperlipidaemia with bezafibrate (abstract 1296). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999, September 26-29. San Francisco.
101. Thomas JC, Lopes-Virella MF, Del Bene VE, Cerveny JD, Taylor KB, McWhorter LS, et al. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy. 2000;20:727-34.
102. De Luis DA, Aller R, Rachiller P, Ignacio Tortosa J. Reversibilidad de hiperlipemia severa secundaria a indinavir con fenofibrato micronizado. Med Clin (Barc). 1999;113:716-7.
103. Palacios R, Santos J, González M, Ruiz J, Valdivielso P, Márquez M, et al. Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30:356-7.
104. Negredo E, Rey-Joly C, Puig J, Bonjoch A, Moltó J, Blanco A, et al. Ezetimibe, a selective inhibitor of cholesterol absorption, as a new strategy for treatment of hypercholesterolemia secondary to antiretroviral therapy. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005, December 16-19. Washington.
105. Palacios R, Santos J, González M, Ruiz J, Valdivielso P, Márquez M, et al. Efficacy and safety of fenofibrate for the treatment of hypertriglyceridaemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:251-3.
106. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-13.
107. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, et al; NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-77.
108. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and two HMG-CoA reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45:3445-50.
109. Carr RA, Andre AK, Bertz RJ. Concomitant administration of ABT-378/ritonavir: results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin (abstract 1644). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000, September 17-20. Toronto.
110. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, et al; AIDS Clinical Trials Group A5108 Team. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005;39:307-12.
111. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-27.
112. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998;34:155-62.
113. Calza L, Manfredi R, Colangeli V, Tampellini L, Sebastiani T, Pocaterra D, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005;19:1051-8.
114. Wohl DA, Tien HC, Busby M, Cunningham C, Macintosh B, Napravnik S, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005;41:1498-504.
115. Gerber MT, Mondy KE, Yarasheski KE, Drechsler H, Claxton S, Stoneman J, et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis. 2004;39:419-25.
116. De Truchis P, Kirstetter M, Perier A, Meunier C, Gardette J, Melchior JC; Maxepa-VIH-1 Study Group. Treatment of hypertriglyceridemia in HIV-infected patients under HAART by (n-3) polyunsaturated fatty acids: a double-blind randomized prospective trial in 122 patients (abstract 39). 12th Conference on Retroviruses and Opportunistic Infections; 2005, February 22-25. Boston.
117. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, et al; International AIDS Society-USA. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr. 2002;31:257-75.
118. Law MG, D'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr W, Reiss P, et al. Cardio- and cerebrovascular events and predicted rates of myocardial infartion in the D.A.D study. 11th Conference on Retroviruses and Opportunistic Infections. 2004, February 8-11. San Francisco.
119. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol. 1998;46:49-53.